Register by January 15 and SAVE up to $200 Premier Sponsors Corporate Sponsors Conference: February 3-5 | Exhibits: February 3-4 Moscone North Convention Center | San Francisco, CA PLENARY KEYNOTES When Drug Research is Personal John F. Crowley, Founder, Novazyme Pharmaceuti cals, Inc. Technology, Aging, and the Brain Biotechnologies GmbH ® Gary W. Small, M.D., Professor, Meso Scale Discovery David Geff en School of Medicine, University of California, Los Angeles Chips, Clones and Living Beyond 100 Paul J.H. Schoemaker, Ph.D., Lead Sponsoring Publicati ons M.B.A., Professor, Wharton School of Business Corporate Support Sponsors Co - Sponsors The State of California Cambridge Healthtech Institute • 250 First Avenue, Suite 300, Needham, MA 02494 Telephone: 781-972-5400 or Toll-Free in the U.S. 888-999-6288 • Fax: 781-972-5425 Tri-Conference.com Media Partners CONFERENCE-AT-A-GLANCE Tuesday, February 2 The Open Access Publisher 8:00 AM Morning Short Course Registration and Coffee 9:00 - 12:00 PM Morning Short Courses (Courses 1-6) 10:15 - 10:30 Networking Coffee Break 1:00 - 2:00 Afternoon Short Course Registration 2:00 - 5:00 Afternoon Short Courses (Courses 7-12) 3:15 - 3:30 Networking Refreshment Break 5:00 Close of Day Wednesday, February 3 7:00 AM Registration and Morning Coffee 8:00 - 9:40 Plenary Keynotes 9:40 - 11:00 Grand Opening Refreshment Break in the Exhibit Hall Nanomedicine 11:00 - 12:40 PM Concurrent Channels 12:40 - 1:45 Sponsored Luncheon Presentations or Lunch on Your Own 1:45 - 2:15 Dessert in the Exhibit Hall 2:15 - 4:20 Concurrent Channels 4:20 - 5:20 Reception in the Exhibit Hall (Sponsorship Available) 5:20 - 6:20 Break-out Discussions 6:20 Close of Day Sponsoring Organizations Thursday, February 4 8:25 - 10:30 AM Concurrent Channels 10:30 - 11:30 Poster Competition, Refreshment Break & Raffles in the Exhibit Hall 11:30 - 12:30 PM Concurrent Channels 12:30 - 1:45 Sponsored Luncheon Presentations or Lunch on Your Own 1:45 - 2:15 Ice Cream Refreshment Break in the Exhibit Hall 2:15 - 3:05 Plenary Keynote Session 3:05 - 3:45 Refreshment Break in the Exhibit Hall CHI’s Intro-Net: 3:45 - 5:50 Concurrent Channels 5:50 Close of Day Networking at Its Best! Friday, February 5 Maximize Your Experience 8:30 - 10:20 AM Concurrent Channels onsite at the Molecular Medicine Tri-Conference! 10:20 - 11:00 Coffee Break The Intro-Net offers you the opportunity to set up 11:00 - 12:00 PM Concurrent Channels meetings with selected attendees before, during and after this conference, allowing you to connect 12:00 - 1:00 Sponsored Luncheon Presentations or Lunch on Your Own to the key people that you want to meet. This online 1:00 - 3:05 Concurrent Channels system was designed with your privacy in mind and is only available to registered session attendees of 3:05 Close of Conference this event. 2 Online: Tri-Conference.com Email: [email protected] Fax: 781-972-5425 8 * 7 PRE-CONFERENCE SHORT COURSES* Tuesday, February 2 *Separate Registration Required MORNING COURSES: 9AM – 12PM AFTERNOON COURSES: 2PM – 5PM (SC1) APPLYING NEXT GENERATION SEQUENCING TECHNOLOGIES TO RESEARCH (SC7) BEST PRACTICES IN TRANSLATIONAL & PERSONALIZED MEDICINE Introduction to New Technologies and Application in Research • Real world solutions currently in place in pharma, national labs, academia, and industry • Technologies for newest platforms for next generation sequencing • Building collaborations and sharing biological data between Big Pharma • Strategies and tools for managing data • Bridging the gap between bench and bedside • Demonstration of how tools can be applied to research • Informatics solutions that link data from the clinic with cutting edge research Course Moderator: Course Instructors: Stanley Gloss, Founding Partner Managing Director, BioTeam, Inc. Jeffrey S. Barrett, Ph.D., FCP, Pediatrics Director, Pediatric Pharmacology Research Unit, The Course Instructors: Children’s Francisco M. De La Vega, D.Sc., Distinguished Scientific Fellow, Computational Genomics Research, Hospital of Philadelphia Genetics Systems R&D, Life Technologies Lisa LaLuna, Senior Vice President, Corporate Development & Implementation, Giles Day, Senior Director, BBC Informatics, Pfizer Biotherapeutics & Bioinnovation Center ePharmaSolutions Ronald W. Davis, Ph.D., Professor, Biochemistry & Genetics, and Director, Stanford Genome Jeremy Packer, Head, Bioinformatics, Abbott Technology Center, Stanford University Faye D. Schilkey, Associate Director, NM Sequencing Center, National Center for Genome (SC2) One CaSe Study In BreaSt CanCer- three PerSPeCtIveS Resources Illustrating Current Challenges in Personalized Medicine • Overview of case study • Clinical perspective (SC8) STRATEGIES FOR MOLECULAR DIAGNOSTIC COMPANIES • Diagnostic and biomarker perspective Achieving Success in Rapidly Changing Markets • Payer perspective • Why and how diagnostics markets have changed Course Instructors: • Strategies for success: conventional or new markets? Michael Liebman, Ph.D., Managing Director, Strategic Medicine, Inc. • Major business model questions including partnering Laura J. Esserman, Professor, Surgery, University of California, San Francisco Medical Center • How to obtain your next round of funding Tracey Colpitts, Ph.D., Manager, Abbott Molecular Course Instructors: Keith F. Batchelder, Chief Executive Officer, Genomic Healthcare Strategies (SC3) MIGhty MItOChOndrIa: their relevance to disease and translational Peter S. Miller, Chief Operating Officer, Genomic Healthcare Strategies Medicine • Mitochondria in disease and drug induced toxicity (James Dykens) (SC9) FRAGMENT-INSPIRED MEDICINAL CHEMISTRY • Assessing mitochondrial function preclinically (Yvonne Will) • Fragment-based approaches as platforms for medicinal chemistry • Non-invasive mitochondrial assessment in the clinic (Robert Wiseman) • Fragment-based methods that inspire fresh approaches to lead generation Course Leader: • Optimization of fragment hits Yvonne Will, Ph.D., Compound Safety Prediction- WWMC, Cell Based Assays and Mitochondrial • Combining technology with fragment-based methods to advance medicinal chemistry Biology, Pfizer R&D • Facing the challenge of applying fragment-based approaches when structural information is Course Instructors: James Dykens, Ph.D., Drug Safety R&D, Pfizer Inc not available Yvonne Will, Ph.D., Compound Safety Prediction- WWMC, Cell Based Assays and Mitochondrial • Promises and pitfalls of surface plasmon resonance (SPR) for fragment methods Biology, Pfizer R&D Course Instructors: Robert Wiseman, Ph.D., Associate Professor, Department of Physiology, Michigan State University Michelle Arkin, Ph.D., Associate Director, Biology, Small Molecule Discovery Center, Pharmaceutical Chemistry, University of California, San Francisco (SC4) ADDRESSING SAFETY CONCERNS FOR BIOLOGICAL DRUGS Daniel A. Erlanson, Ph.D., Co-founder, Carmot Therapeutics, Inc. • Overview of challenges pertaining to safety for biologics • Safety assessments at pre-clinical and clinical stage (SC10) TRANSPORTER-MEDIATED DRUG-DRUG INTERACTION POTENTIAL • Use of new assays, animal models and biomarkers for early predictions Strategies for in vitro Characterization • Clinical relevance of transporter DDI’s • Regulatory guidelines and their interpretations Course Instructors: • In vitro, cell based models for evaluating transporter interactions of substrates and inhibitors Hong Wang, Ph.D., DABT, Safety Assessment, Genentech Inc. • Case study: minimizing p-glycoprotein interactions as a barrier to CNS penetration Kathleen Meyer, MPH, Ph.D., DABT, Senior Director, Preclinical Safety Evaluation, XOMA (US) LLC Course Instructors: Phil Burton, Ph.D., Chief Executive Officer & Chief Scientific Officer, ADMETRx, Inc. (SC5) TARGETING CANCER STEM CELLS WITH BIOLOGICS Xingrong Liu, Ph.D., Senior Scientist, DMPK, Genentech, Inc. • Novel nanoparticle fusion proteins, tr1 and tr4, that achieve normal p21 delivery to p53/p21 Joseph A. Ware, Ph.D., Senior Scientist, Clinical Pharmacokinetics and Pharmacodynamics, mutated tumors (tr1) and inhibition of notch signaling (tr4) resulting in tumor eradication Development Sciences, Genentech, Inc. • Differentiation versus self-renewal: changing cancer stem cell fate by targeting stem cell pathways • Cancer stem-like cells: isolation using biological criteria and use in drug discovery and development (SC11) BaSIC IMMerSIOn: CuttInG edGe SCIenCe & teChnology fOr • Cd47: an adverse prognostic factor and therapeutic antibody target on human acute myeloid Biotech & PHARMA leukemia stem cells • Gain a fundamental understanding of the science and technology driving the Biotech/ • Identification of stem cell markers in the normal prostate and prostate cancer Pharma industry Course Instructors: • Learn basic scientific terminology used by researchers in the life sciences Agamemnon Epenetos, Ph.D., FRCP, Chairman, Trojantec Ltd. • Designed for the non-scientist working with or in the biotech/pharma industry Austin Gurney, Ph.D., Vice President, Molecular and Cellular Biology, OncoMed Pharmaceuticals, Inc. • Immersion course on the biotech basics; Recombinant DNA, Proteins, Stem Cells, Biologics, Jennie P. Mather, Ph.D., Senior Vice President, Stem Cell Research, MacroGenics, Inc. Drug Discovery and Drug Development Ravi Majeti M.D., Ph.D., Assistant Professor, Division of Hematology, Stanford Cancer Center, Institute Class Materials Include: The Primer: A Biotechnology Guide for Non-Scientists for Stem Cell Biology and Regenerative Medicine Course Instructor: Kevin G. Leong, Ph.D., Scientist,